Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 7/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.42 |
| ▸ | HTR3A | P46098 | 4/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006076 | 0.92 | HTR3A (0.42) | NR1H3NR1H2HTR3AF2RL3PARP1 | |
| SCHEMBL1006345 | 0.87 | NR1H3 (0.53) | NR1H3NR1H2HTR3ANAAAHTR6 | |
| SCHEMBL1006343 | 0.87 | NR1H3 (0.53) | NR1H3NR1H2HTR3ANAAAHTR6 | |
| SCHEMBL1005752 | 0.85 | NAAA (0.49) | NR1H3NR1H2HTR3ANAAAKCNH2 | |
| SCHEMBL1005084 | 0.80 | PARP1 (0.41) | NR1H3NR1H2HTR3AF2RL3PARP1 | |
| SCHEMBL1005082 | 0.80 | PARP1 (0.41) | NR1H3NR1H2HTR3AF2RL3PARP1 | |
| SCHEMBL1004307 | 0.79 | HCAR2 (0.47) | PARP1NAAAHTR6LMNAHTT | |
| SCHEMBL1008240 | 0.78 | NR1H3 (0.49) | NR1H3NR1H2HTR3ANAAAKCNH2 | |
| SCHEMBL1008242 | 0.78 | NR1H3 (0.49) | NR1H3NR1H2HTR3ANAAAKCNH2 | |
| Lithium Ion SCHEMBL1005750 | 0.78 | MAP4K4 (0.49) | NR1H3NR1H2HTR3APARP1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863271-B2 | 2-aminobenzoxazole carboxamides as 5HT3 modulators | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2061460-A2 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | Albany Molecular Research, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080255114-A1 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | AMR TECHNOLOGY, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008019372-A2 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255114-A1 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | HTR3E, HTR3C, HTR3A | NR1H3 4594/4885NR1H2 4529/4885HTR3A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.